Home › Companies › SMMT

Summit Therapeutics

Market cap $8.53B 799.8M shares (10-Q, Oct 30, 2026) × $10.67 close Nov 17, 2026

Most recent annual filing: 2026-02-15

Catalyst timeline

6 trackedQuarter catalyst calendar →
  1. ivonescimab NSCLC interim4Q 2026ivonescimab NSCLC interim, 4Q 2026, material
  2. HARMONi-GU1 corporate update4Q 2026HARMONi-GU1 corporate update, 4Q 2026, routine
  3. EA2251 / HARMONi-GU1 corporate update4Q 2026EA2251 / HARMONi-GU1 corporate update, 4Q 2026, routine
  4. Share authorization increase financingDec 31, 2026Share authorization increase financing, Dec 31, 2026, routine
  5. HARMONi-3 non-squamous readout1H 2027HARMONi-3 non-squamous readout, 1H 2027, notable
  6. AstraZeneca preferred stock lock-up corporatelate 2027AstraZeneca preferred stock lock-up corporate, late 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

SCOPE IO · Lunit

AI-powered pathology platform for tumor microenvironment analysis using H&E whole-slide images; supports biomarker discovery, patient stratification, and immuno-oncology research

Capital (as filed)

Cash
$151M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$479M Sep 30, 2026
Operating cash flow
−$160M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$630M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Offering documents (3)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (22)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (22 calls)

Every verdict Biotech Distilled has published on Summit Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Buy core Summit Therapeutics (SMMT): Scientific Deep Dive for Ivonescimab and Pipeline Products Strong cooperative-binding science, historic insider conviction, and pristine cash runway make SMMT attractive despite FDA geographic data risk on the OS endpoint.
  2. Buy core UPDATE: Summit Therapeutics (SMMT) - EoY 2025 Update Accelerated HARMONi-3 interim catalyst and pristine balance sheet keep the thesis intact.
  3. Buy core UPDATE: Summit Therapeutics (SMMT) - ELCC 2026 Data Compelling intracranial efficacy data at ELCC strengthens the BLA package and the fundamental thesis.
  4. Buy core UPDATE: Summit Therapeutics (SMMT) - Q1 2026 Earnings, an iDMC Pass, and an ASCO Plenary Slot HARMONi-6 OS ASCO Plenary slot is a major catalyst escalation; thesis intact though asymmetry is shifting at higher price.
  5. Buy core UPDATE: Summit Therapeutics (SMMT) - The 25% Panic Into ASCO 25% single-session crash overdiscounts FDA risk; asymmetry has flipped back in the buyer's favor at $16.11.
  6. Buy core UPDATE: Summit Therapeutics (SMMT) - The Plenary Delivered. The Tape Didn't. HARMONi-6 OS HR 0.66 published in The Lancet validates the mechanism; at $15.71 the entry compensates for FDA risk more than at prior levels.
  7. Buy core UPDATE: Summit Therapeutics (SMMT) - The Insiders Got the Green Light Board clearing C-suite to buy through ATM at ~$15 is a confirmatory insider signal reinforcing the thesis.
  8. Hold UPDATE: Summit Therapeutics (SMMT) - The $500M Bait-and-Switch $500M underwritten offering at a punitive discount damages insider-signal credibility and creates near-term technical supply overhang, warranting a downgrade despite unchanged science.
  9. Buy core UPDATE: Summit Therapeutics (SMMT) - The Deal Got Pulled Withdrawal of the $500M offering removes the dilution trigger that caused the HOLD downgrade; asymmetry tilts back toward buyer at $13.08 though capital-structure uncertainty remains.
  10. Buy core UPDATE: Summit Therapeutics (SMMT) - The Western OS Number Just Caught Up Western OS HR converging to 0.76 at 23.2 months follow-up removes the post-hoc slicing critique and materially de-risks the FDA geography concern ahead of the PDUFA.
  11. Buy core UPDATE: Summit Therapeutics (SMMT) - The Form 4s Landed $52M of confirmed insider buying at $13.17 validates the June 3 signal; new $380M ATM and strong Q2 cash position secure runway through all near-term catalysts.
  12. Buy core UPDATE: Summit Therapeutics (SMMT) - China Says Yes, Round Three Third NMPA approval validates the HARMONi-6 dataset via regulatory audit; new HARMONi-GU1 bladder cancer Phase III extends the pipeline-in-a-product thesis.
  13. Buy core UPDATE: Summit Therapeutics (SMMT) - The Drug Escapes the Lung First non-lung Phase III OS win (HARMONi-GI1 vs. durvalumab in biliary cancer) and Lancet Oncology publication of HARMONi strengthen the platform case; WCLC September 15 is the next key catalyst.
  14. Buy core UPDATE: Summit Therapeutics (SMMT) - Keytruda Just Lost a Head-to-Head on Survival HARMONi-2 OS topline shows ivonescimab beating pembrolizumab on survival — the third head-to-head OS win over a checkpoint inhibitor — though no hazard ratio yet prevents an upgrade.
  15. Buy core UPDATE: Summit Therapeutics (SMMT) - The Hazard Ratio Arrives HARMONi-2 OS HR 0.73 vs. pembrolizumab with 0.58 in PD-L1-high subgroup is a strong HARMONi-7 prior; author maintains BUY but notes reduced asymmetry after 26% run and cautions against adding at $18.42.
  16. Hold UPDATE: Summit Therapeutics (SMMT) - The Western Confidence Interval Crosses One Western subgroup CI of 0.52–1.10 crosses 1.0 and global p-value is nominal; at $17.40 the price no longer compensates adequately for a genuine coin-flip FDA binary 60 days out.
  17. Buy core UPDATE: Summit Therapeutics (SMMT) - AstraZeneca Writes a $2 Billion Check AstraZeneca's $2B convertible preferred at an 18.6% premium transforms the CRL downside from 'busted binary' to 'delay with a war chest,' restoring the asymmetry in the buyer's favor.
  18. Buy core UPDATE: Summit Therapeutics (SMMT) - The Fine Print Behind the $2 Billion 8-K fine print confirms AZ has no veto over takeovers and is locked up for a year, removing supply overhang fears and supporting the BUY thesis.
  19. Buy core UPDATE: Summit Therapeutics (SMMT) - The MOU Gets a Phase III AZ/Daiichi Sankyo Phase III in TNBC with Datroway expands the pipeline-in-a-product thesis into breast cancer on capital-efficient terms without changing the November binary.
  20. Buy core UPDATE: Summit Therapeutics (SMMT) - The Biliary Number Arrives HARMONi-GI1 OS HR 0.75 with tight CI and a new U.S. registration-enabling trial (EA2251) strengthen the 'delayed not broken' downside case 19 days before the PDUFA.
  21. Buy core UPDATE: Summit Therapeutics (SMMT) - Clearing the Desk Before the Binary Going-concern warning removed, AZ conversion vote passed, and HARMONi-3 squamous PFS pinned to Q4; balance sheet questions settled ahead of the November 14 binary.
  22. Hold UPDATE: Summit Therapeutics (SMMT) - The CRL Lands FDA CRL confirms OS is the gate; molecule is intact but next approval opportunity depends on HARMONi-3 OS data months away, making adding before that readout unreasonable.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (7 quotes from 6 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (57)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)